A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., Schuler, M.
Published in Annals of oncology (01.09.2019)
Published in Annals of oncology (01.09.2019)
Get full text
Journal Article
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S.N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., Zanghi, J.A., Leutgeb, B., Felip, E.
Published in Annals of oncology (01.08.2023)
Published in Annals of oncology (01.08.2023)
Get full text
Journal Article
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702]
Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S.N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., Zanghi, J.A., Leutgeb, B., Felip, E.
Published in Annals of oncology (01.05.2024)
Published in Annals of oncology (01.05.2024)
Get full text
Journal Article
IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer
Plate, S, Zvirbule, Z, Kasperova, S
Published in International journal of gynecological cancer (01.05.2015)
Published in International journal of gynecological cancer (01.05.2015)
Get full text
Journal Article
IFOSFAMIDUM AS PALLIATIVE TREATMENT FOR ADVANCED OVARIAN CANCER: IGCS-0063 06. Ovarian Cancer
Plate, S, Zvirbule, Z, Kasperova, S
Published in International journal of gynecological cancer (01.05.2015)
Published in International journal of gynecological cancer (01.05.2015)
Get more information
Journal Article
2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC)
Joly, F, Pautier, P, Vergote, I, Melichar, B, Kutarska, E, Hall, G, Lisayankaya, A, Reed, N, Oaknin, A, Ostapenko, V, Zvirbule, Z, Chetaille, E, Shoaib, M, Green, J.A, Heutte, N
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)
Oza, A.M, Selle, F, Davidenko, I, Korach, J, Mendiola, C, Gocze, P, Pautier, P, Chmielowska, E, Bamias, A, DeCensi, A, Zvirbule, Z, Gonzalez-Martin, A, Hegg, R, Joly, F, Zamagni, C, Gadducci, A, Deurloo, R, Revil, C, Robb, S, Colombo, N
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Zielinski, C.C, Lang, I, Inbar, M, Kahan, Z, Greil, R, Beslija, S, Stemmer, S.M, Zvirbule, Z, Steger, G.G, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D, Brodowicz, T
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)
Wakelee, H.A, Zvirbule, Z, De Braud, F, Kingsley, C.D, Mekhail, T, Schütte, W, Lena, H, Lawler, W, Braiteh, F, Cosgriff, T, Kaen, D, Boyer, M, Hsu, J, Phan, S, Novello, S
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Get full text
Journal Article
Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)
Hirsch, F.R, Govindan, R, Zvirbule, Z, Braiteh, F, Rittmeyer, A, Belda Iniesta, C, Isla, D, Cosgriff, T, Boyer, M, Ueda, M, Phan, S, Gandara, D
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Get full text
Journal Article
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
Brufsky, A., Kim, S.B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J.H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., McNally, V., Miles, D., Loi, S.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
Lang, I, Inbar, M.J, Kahán, Z, Greil, R, Beslija, S, Stemmer, S.M, Kaufman, B, Zvirbule, Z, Steger, G.G, Messinger, D, Brodowicz, T, Zielinski, C
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
Inbar, M, Lang, I, Kahán, Z, Greil, R, Beslija, S, Stemmer, S.M, Kaufman, B, Zvirbule, Z, Steger, G.G, Zielinski, C.C
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto, M., Zvirbule, Z., Alvarez, R., Chewaskulyong, B., Herraez Baranda, L.A., Shearer-Kang, E., Liu, X., Tosti, N., Castro Sanchez, A.Y., Zanghi, J., Felip, E.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahán, Z, Taskova, V, Kaufmann, B, Zielinski, C.C
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto, M., Felip, E., Zvirbule, Z., Baranda, L.A. Herraez, Chanu, P., Kshirsagar, S., Maiya, V., Pozzi, E., Restuccia, E.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
244MO Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC
Cappuzzo, F., Zvirbule, Z., Korbenfeld, E.P., Kolb-Sielecki, J., Isla Casado, D., Castro Sanchez, A.Y., Bustillos, A., Liu, L.X., Young, F., Majem, M.
Published in ESMO open (01.03.2024)
Published in ESMO open (01.03.2024)
Get full text
Journal Article
Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer
Al-Batran, S-E., Zvirbule, Z., Lordick, F., Thuss-Patience, P., Just, M., Bitzer, M., Brass, V., Krilova, A., Maurus, D., Türeci, Ö., Sahin, U.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article